REG-Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Genmab reported positive Phase 2 data for epcoritamab in first-line treatment of diffuse large B-cell lymphoma (DLBCL) in elderly patients. In the EPCORE DLBCL-3 trial, epcoritamab monotherapy achieved a 67% overall response rate and 58% complete response rate in patients ineligible for anthracycline-based chemotherapy. In the EPCORE NHL-2 trial, the combination of epcoritamab with R-mini-CHOP yielded a 93% overall response rate and 86% complete response rate, with high rates of sustained minimal residual disease negativity.
Key figures
- Drug Name
- epcoritamab
- Phase Of Trial
- Phase 2
- Combination cr
- 86%
- Monotherapy cr
- 58%
- Combination orr
- 93%
- Monotherapy orr
- 67%
- Monotherapy pfs
- 13.0 months
- Combination mrd negativity
- 95%
- Monotherapy mrd negativity
- 92%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.